scholarly journals Anti-Programmed Cell Death Protein 1 Antibody Expressing Pluripotent Killer T-Lymphocytes

2020 ◽  
Author(s):  
Keyword(s):  
Cell Death ◽  
T Lymphocytes ◽  
Programmed Cell Death ◽  
Cell Death Protein

scholarly journals CRISPR knock out of programmed cell death protein 1 enhances anti-tumor activity of cytotoxic T lymphocytes

Oncotarget ◽  
2017 ◽  
Vol 9 (4) ◽  
pp. 5208-5215 ◽  
Author(s):  
Zhilong Zhao ◽  
Long Shi ◽  
Wei Zhang ◽  
Jinsheng Han ◽  
Shaohui Zhang ◽  
...  
Keyword(s):  
Cell Death ◽  
T Lymphocytes ◽  
Programmed Cell Death ◽  
Cytotoxic T Lymphocytes ◽  
Knock Out ◽  
Anti Tumor Activity ◽  
Cell Death Protein

scholarly journals Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Tao Shen ◽  
Liangjing Zhou ◽  
Hua Shen ◽  
Chengfei Shi ◽  
Shengnan Jia ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cell Death ◽  
T Lymphocytes ◽  
Programmed Cell Death ◽  
Prognostic Value ◽  
Cd8 T Lymphocytes ◽  
Cell Death Protein

scholarly journals Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation

2020 ◽  
Vol 9 (1) ◽  
pp. 1738797 ◽  
Author(s):  
Ieva Saulite ◽  
Desislava Ignatova ◽  
Yun-Tsan Chang ◽  
Christina Fassnacht ◽  
Florentia Dimitriou ◽  
...  
Keyword(s):  
Cell Death ◽  
T Lymphocytes ◽  
Programmed Cell Death ◽  
Sézary Syndrome ◽  
Tumor Proliferation ◽  
Sezary Syndrome ◽  
Cell Death Protein

scholarly journals Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future

2017 ◽  
Vol 2017 ◽  
pp. 1-10 ◽  
Author(s):  
Ece Esin
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Checkpoint Inhibitors ◽  
Innate Immune ◽  
Small Subset ◽  
New Class ◽  
Combination Strategies ◽  
Combination Methods ◽  
Immune Editing ◽  
Cell Death Protein

In the last decade, we have gained a deeper understanding of innate immune system. The mechanism of the continuous guarding of progressive mutations happening in a single cell was discovered and the production and the recognition of tumor associated antigens by the T-cells and elimination of numerous tumors by immune-editing were further understood. The new discoveries on immune mechanisms and its relation with carcinogenesis have led to development of a new class of drugs called immunotherapeutics. T lymphocyte-associated antigen 4, programmed cell death protein 1, and programmed cell death protein ligand 1 are the classes drugs based on immunologic manipulation and are collectively known as the “checkpoint inhibitors.” Checkpoint inhibitors have shown remarkable antitumor efficacy in a broad spectrum of malignancies; however, the strongest and most durable immune responses do not last long and the more durable responses only occur in a small subset of patients. One of the solutions which have been put forth to overcome these challenges is combination strategies. Among the dual use of methods, a backbone with either PD-1 or PD-L1 antagonist drugs alongside with certain cytotoxic chemotherapies, radiation, targeted drugs, and novel checkpoint stimulators is the most promising approach and will be on stage in forthcoming years.

Sign in / Sign up

Export Citation Format

Share Document